[go: up one dir, main page]

WO2002039996A3 - Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists - Google Patents

Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists Download PDF

Info

Publication number
WO2002039996A3
WO2002039996A3 PCT/US2001/044161 US0144161W WO0239996A3 WO 2002039996 A3 WO2002039996 A3 WO 2002039996A3 US 0144161 W US0144161 W US 0144161W WO 0239996 A3 WO0239996 A3 WO 0239996A3
Authority
WO
WIPO (PCT)
Prior art keywords
antagonists
estramustine phosphate
combined therapy
against tumors
therapy against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/044161
Other languages
French (fr)
Other versions
WO2002039996A2 (en
Inventor
Jeffrey H Buchalter
Ivan D Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Pharmacia and Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co
Priority to AU2002228648A priority Critical patent/AU2002228648A1/en
Publication of WO2002039996A2 publication Critical patent/WO2002039996A2/en
Publication of WO2002039996A3 publication Critical patent/WO2002039996A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating tumors in a mammal, including humans, in need of such a treatment including administering simultaneously, separately or sequentially to said mammal estramustine phosphate and a LHRH agonist or antagonist, in amounts sufficient to achieve a therapeutically useful effect.
PCT/US2001/044161 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists Ceased WO2002039996A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002228648A AU2002228648A1 (en) 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71460600A 2000-11-16 2000-11-16
US09/714,606 2000-11-16

Publications (2)

Publication Number Publication Date
WO2002039996A2 WO2002039996A2 (en) 2002-05-23
WO2002039996A3 true WO2002039996A3 (en) 2003-03-20

Family

ID=24870732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044161 Ceased WO2002039996A2 (en) 2000-11-16 2001-11-06 Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists

Country Status (2)

Country Link
AU (1) AU2002228648A1 (en)
WO (1) WO2002039996A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4905624B2 (en) * 2003-10-31 2012-03-28 学校法人 久留米大学 Combination therapy of peptide vaccine administration and estramustine treatment
WO2005041981A1 (en) * 2003-10-31 2005-05-12 Kurume University Combination therapy of peptide vaccination and estramustine treatment
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX392823B (en) 2016-12-21 2025-03-24 Avecho Biotechnology Ltd PHOSPHORYLATION PROCESS OF A COMPLEX ALCOHOL

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029105A2 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795882A (en) * 1992-06-22 1998-08-18 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
WO1998029105A2 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
WO1998029123A1 (en) * 1996-12-30 1998-07-09 Bone Care International, Inc. Method of treating prostatic diseases using active vitamin d analogues

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTA UROLOGICA JAPONICA, vol. 41, no. 9, 1995, pages 683 - 685, ISSN: 0018-1994 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, MIYAJIMA AKIRA ET AL: "A case of huge prostate cancer.", XP002224436, Database accession no. PREV199698596655 *
SHIINA H ET AL: "IMMUNOHISTOCHEMICAL ANALYSIS OF ESTRAMUSTINE BINDING PROTEIN WITH PARTICULAR REFERENCE TO PROLIFERATIVE ACTIVITY IN HUMAN PROSTATIC CARCINOMA", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 32, no. 1, 15 June 1997 (1997-06-15), pages 49 - 58, XP001079665, ISSN: 0270-4137 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841342B2 (en) 2002-08-09 2014-09-23 Vital Health Sciences Pty. Ltd. Carrier
US9168216B2 (en) 2005-06-17 2015-10-27 Vital Health Sciences Pty. Ltd. Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
US9314527B2 (en) 2010-03-30 2016-04-19 Phosphagenics Limited Transdermal delivery patch
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound

Also Published As

Publication number Publication date
WO2002039996A2 (en) 2002-05-23
AU2002228648A1 (en) 2002-05-27

Similar Documents

Publication Publication Date Title
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2005107726A3 (en) Method for the treatment of back pain
WO2003045434A3 (en) Endothelin antagonists ina method and composition for potentiating an opiate analgesic
WO2000038665A3 (en) Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2002005791A3 (en) Antitumor combination comprising an aromatase inhibitor and an egfr antagonist or inhibitor
AU2003268144A1 (en) Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
WO2003070191A8 (en) Tamper-resistant transdermal opioid delivery devices
EP1186304A3 (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
WO1999045920A3 (en) The use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
WO2003034995A3 (en) Integrin targeting compounds
WO2004091540A3 (en) Methods of treating pain and compositions for use therefor
WO2005000212A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors
WO2005000214A3 (en) Method for treating diseases using hsp90-inhibiting agents in combination with antibiotics
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
WO2002039996A3 (en) Combined therapy against tumors comprising estramustine phosphate and lhrh agonists or antagonists
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
HU9503625D0 (en) Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema
WO2004071413A3 (en) Method and composition for potentiating an opiate analgesic
WO2000053148A3 (en) Methods and compositions for treating erectile dysfunction
BR0307022A (en) Method of treating a patient who needs analgesia
MY126321A (en) Use of (alpha)-adrenoreceptor antagonists in the prevention and treatment of cancer.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP